Abstract: This invention provides methods for promoting and/or restoring neurite outgrowth and neuronal regeneration by contacting an injured neuron with an inhibitor of low density lipoprotein receptor-related protein-1 (LRP-1).

Abstract: A programmable receptor complex expressed by an immunocyte, wherein the programmable receptor complex includes a plurality of native or endogenously-expressed receptor subunits, wherein at least one of the plurality of native or endogenously-expressed receptor subunits has been engineered or modified to include an Fc?RI receptor component or a biotin-binding component, and wherein the Fc?RI receptor component or biotin-binding component is operative to bind to a target detector molecule that binds to or otherwise interacts with a predetermined target.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.

Abstract: Provided are a Haemadipsa sylvestris antithrombotic peptide Sylvestin and the use thereof, falling within the technical field of biomedicine. The Haemadipsa sylvestris antithrombotic peptide sylvestin can inhibit FXIIa and kallikrein, has anti-thrombus/infarction effects and alleviates injuries caused by cerebral ischemia, and can also be used in the preparation of inhibitors of FXIIa and kallikrein and drugs for anti-thrombus/infarction and anti-cerebral ischemic injuries.

Abstract: Embodiments of the disclosure relate generally to B virus epitopes, and more specifically to B virus epitopes and monoclonal antibodies (MABs) that can distinguish between different B viruses specific to different hosts and can further neutralize said viruses; compositions containing the epitopes and MABs and nucleic acids encoding the epitopes and MABs; and specific B virus peptides and MABs that can be used in diagnostic assays or as sources for vaccines or other therapeutic interventions.

Abstract: The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy. The present invention furthermore describes an in vitro transcription method, in vitro methods for expression of this antibody using the RNA according to the invention and an in vivo method.

Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Borrelia antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating lyme disease in a subject using said composition and method of generation.

Abstract: The presently disclosed subject matter provides antigen-binding proteins (e.g., chimeric antigen receptors) and antibodies or antigen-binding portions thereof that bind to a Foxp3 peptide/MHC molecule complex. Such antibodies, fusion proteins and conjugates thereof are useful for inhibiting regulatory T cells and treating cancers.

Abstract: Disclosed herein are methods of delivering an agent to a subject. Further disclosed herein are methods of treating a disease or disorder in a subject. The methods may include administering to the subject a chondroitinase polypeptide or a polynucleotide encoding a chondroitinase polypeptide in an amount sufficient to degrade glycosaminoglycans, and administering to the subject the agent. The methods may further include administering a hyaluronidase polypeptide or a polynucleotide encoding a hyaluronidase.

Abstract: A method of treating a cancer in a subject in need thereof is disclosed. The cancer can be an esophageal cancer, a uterine cancer, a liver cancer, or a cholangiocarcinoma. The method comprises administering to the subject an effective amount of an anti-Dkk-1 antibody or antigen binding-fragment thereof, wherein the subject is determined to have a constitutively activating mutation of the beta-catenin protein.

Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.

Abstract: Described herein are peptides and antibodies for prevention and/or therapeutic treatment of mammals, including humans, against systemic lupus erythematosus, as well as diagnosing the presence or absence of antibodies related to increased or decreased risk of developing SLE and/or to disease grading, staging, and/or prognosis.

Abstract: Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.

Abstract: Methods and systems for administering anti-TNF therapy to subjects who have been determined to display a gene expression response signature established to distinguish between responsive and non-responsive prior subjects who have received the anti-TNF therapy.

Abstract: Methods for reducing relapse rate or preventing occurrence of tumor relapse in a subject treated with immunotherapy, in an absence of an incidence of immunotherapy-related toxicity or in a presence of immunotherapy-related toxicity. Methods for reducing a level of a cytokine or chemokine other than GM-CSF in a subject having an incidence of immunotherapy-related toxicity, the methods comprising administering a recombinant GM-CSF antagonist to the subject. Methods for treating or preventing immunotherapy-related toxicity in a subject, the methods comprising administering to the subject chimeric antigen receptor-expressing T-cells (CAR-T cells), the CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells), and a recombinant hGM-CSF antagonist.

Abstract: A monoclonal antibody, or antigen-binding portion thereof is provided that specifically binds to a region on a mammalian IL-31 protein involved with interaction of the IL-31 protein with its co-receptor, wherein the binding of said antibody to said region is impacted by mutations in a 15H05 epitope binding region selected from: a region between about amino acid residues 124 and 135 of a feline IL-31 sequence represented by SEQ ID NO: 157 (Feline_IL31_wildtype); a region between about amino acid residues 124 and 135 of a canine IL-31 sequence represented by SEQ ID NO: 155 (Canine_IL31); and a region between about amino acid residues 118 and 129 of an equine IL-31 sequence represented by SEQ ID NO: 165 (Equine_IL31). Such antibodies can be in the form of veterinary compositions useful for treating IL-31-mediated disorders in cats, dogs, or horses.

Abstract: The present invention relates to the treatment of inflammatory bowel disease (IBD) with anti-IL36R antibodies.

Abstract: Provided herein are ERFE specific antibodies, compositions and methods of use for detection of ERFE polypeptides.

Abstract: The present disclosure provides anti-KRAS antibodies, and antigen-binding fragments thereof. In certain embodiments, the anti-KRAS antibodies or fragments thereof, are used for the treatment of cancer.

Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Abstract: The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.

Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

Abstract: The present invention relates to a bispecific antibody that binds to human CD19 and CD3, wherein the bispecific antibody is composed of a Fab fragment which specifically recognizes a cell membrane antigen and a single-chain antibody which recognizes a CD3 molecule, where the single-chain antibody which recognizes the CD3 molecule is linked to the C-terminus of the CH1-region peptide fragment of the Fab fragment through a hydrophilic linker peptide-linker; and where the Fab fragment which specifically recognizes a cell membrane antigen contains a Fab structure which specifically recognizes a human CD19 antigen, and the bispecific antibody has the following structure: where the linker peptide-linker is composed of 8-20 hydrophilic amino acids.

Abstract: The disclosure provides antibody agents that bind to a T Cell Immunoglobulin and Mucin Protein-3 (TIM-3) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related nucleic acids, vectors, compositions, and methods of using the anti-TIM-3 antibody agent to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.

Abstract: Formulations and dosage regimens of anti-Blood Dendritic Cell Antigen 2 (BDCA2) antibodies are provided. These formulations and dosage regimens find use in the treatment of BDCA2-associated disorders such as systematic lupus erythematosus, cutaneous lupus eiythernatosus, and discoid lupus erythematosus, and cytokine release syndrome.

Abstract: This present invention relates to a method of stabilizing an aqueous pharmaceutical preparation susceptible to de-gradation by formulating in a dual buffer system wherein the individual buffers are selected from phosphate, aspartate, glutamate, and succinate buffer.

Abstract: The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one matrix metalloprotease (MMP), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one MMP protease, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one MMP protease in a variety of therapeutic, diagnostic and prophylactic indications.

Abstract: The current invention relates to the intermittent dosing of an anti-CSF-1R antibody in combination with macrophage activating agent, corresponding pharmaceutical compositions or medicaments using such combination therapy.

Abstract: The present invention relates to the treatment of or alleviation of signs and symptoms of an acute phase flare-up of generalized pustular psoriasis (GPP) with anti-IL36R antibodies.

Abstract: The present invention relates to methods for reactivating latent HIV-1, treating HIV-1 infection in a subject, and increasing the effectiveness of combination antiretroviral therapy by inhibiting type I interferon signaling. The invention further relates to methods of screening for HIV-1 therapeutics.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

Abstract: Chimeric antigen receptors (CARs) are provided that comprise a CD123-specific antigen recognition domain and IL7Ra transmembrane and intracellular signaling domains (CD123/IL7Ra CARs). In particular embodiments, provided herein are engineered lymphocytes that express and display CD123/IL7Ra CARs, and methods of targeting CD123-positive leukemic cells and treating leukemias, such as acute myeloid leukemia (AML), therewith.

Abstract: Antibodies and methods of using these antibodies are provided which bind human and mouse receptor activator of nuclear factor kappa-B ligand, said antibodies are useful as agents for treating conditions associated with bone-related disorders or skeletal abnormalities caused by cancer.

Abstract: The present invention includes apoptotic compositions and methods for inducing apoptosis of cancer cells independent of NK cells. An apoptotic composition comprises a cooperative combination of antibodies that specifically bind to human DR5, or a cooperative combination of an anti-DR5 antibody and TRAIL. Administration of therapeutically effective amounts of an apoptotic composition induces apoptosis of apoptosis sensitive cancer cells.

Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.

Abstract: Binding proteins that specifically bind to 4-1BB (CD137) are disclosed. More specifically, antibodies that specifically bind to human 4-1BB are disclosed. These binding proteins may be used to treat or to prevent diseases such as cancers by altering the levels or activities of 4-1BB.

Abstract: Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-CD73 antibody in combination with an immuno-oncology agent, such as an anti-PD-1 antibody.

Abstract: The present disclosure concerns an antibody that specifically binds CD38 which is capable of killing a CD38+ cell by induction of apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose of about 20 mg/kg or below. In one embodiment, the medicament is for treating CD38+ multiple Myeloma in humans.

Abstract: The present disclosure relates to anti-CD39 antibodies, and antigen binding portions thereof and their use in treating cancer.

Abstract: The present invention relates to a set of polypeptides and its uses. In particular, the present invention relates to a set of polypeptides whereby this set comprises two polypeptides each of which comprises a targeting moiety “T” binding to an antigen “?” and a fragment of “F” of a functional domain, wherein said two polypeptides are not associated with each other in absence of a substrate that has “A” at (on) its surface and wherein, upon dimerization of “F”, the resulting dimer becomes functional. Furthermore, medical and diagnostic uses of said set are described. Moreover, the present invention relates to nucleic acid molecule(s) encoding said set of polypeptides. The present invention also relates to a vector comprising the nucleotide sequence of nucleic acid molecule(s) encoding said set of polypeptides. Furthermore, the present invention relates to pharmaceutical compositions comprising said set of polypeptides. Moreover, the present invention relates to a kit comprising said set of polypeptides.

Abstract: The disclosure relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD3 epsilon (CD3?), as well as methods of making and using these anti-CD3? antibodies and antigen binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.

Abstract: Disclosed herein are methods of using immune cells expressing chimeric receptors and two or more anti-cancer antibodies that bind cancer antigens in cancer therapy.

Abstract: The present invention provides a method for production of stable and highly specific heterodimeric immunoglobulin constructs, e.g., bispecific antibodies, retaining desirable properties of native IgG and lacking undesirable heavy chain-light chain mispairing, that can simultaneously bind two target molecules and are more potent in the treatment of complex diseases.

Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.

Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.

Abstract: Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.

Abstract: A hybridoma cell line of secreting cyproheptadine monoclonal antibodies with a preservation number of CGMCC No. 14699 belongs to the field of food safety immunological detection. BALB/c mice are immunized through one time immunization with complete freund's adjuvant, three times of booster immunization with incomplete freund's adjuvant and one time of rush immunization with cyproheptadine complete antigen without adjuvant; the spleen cells from BALB/C mice immunized with high potency and low value of IC50 are fused with murine myeloma cells; and then the hybridoma cell line is obtained through indirect competitive ELISA screening and three sub-clones. The monoclonal antibody secreted by this cell line has good specificity and detection sensitivity to cyproheptadine (value of IC50 is 0.37 ng/ml), being suitable for detection of cyproheptadine in food.